false
0001712762
0001712762
2026-11-11
2026-11-11
0001712762
BIAF:CommonStockParValue0.007PerShareMember
2026-11-11
2026-11-11
0001712762
BIAF:WarrantsToPurchaseCommonStockMember
2026-11-11
2026-11-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 11, 2026
bioAffinity
Technologies, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41463 |
|
46-5211056 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
3300
Nacogdoches Road, Suite 216
San
Antonio, Texas 78217
(Address
of principal executive offices, including zip code)
(210)
698-5334
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title
of each class |
|
Trading
Symbols |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.007 per share
|
|
BIAF
|
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market) |
| |
|
|
|
|
| Warrants
to purchase Common Stock |
|
BIAFW |
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01. Other Events.
On
November 11, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing
that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume
for the Company’s noninvasive lung cancer test.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number |
|
Description |
| 99.1 |
|
Press Release issued by bioAffinity Technologies, Inc., dated November 11, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K
to be signed on its behalf by the undersigned hereunto duly authorized.
| Date:
November 17, 2026 |
BIOAFFINITY
TECHNOLOGIES, INC. |
| |
|
| |
By: |
/s/
Maria Zannes |
| |
Name: |
Maria
Zannes |
| |
Title: |
President
and Chief Executive Officer |
Exhibit
99.1
bioAffinity
Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
October
testing volume equals approximately 45% of all tests performed in the previous quarter
SAN
ANTONIO, Texas – November 11, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company
developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics
for skin cancer, today announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly
testing volume for the Company’s noninvasive lung cancer test.
The
October results demonstrate continued growth in test utilization by both established and newly ordering physicians. In October 2026,
235 CyPath Lung tests were performed, representing a 29% increase compared with October 2025. October 2026 testing volume was equivalent
to approximately 45% of the total number of tests performed in Q3 2026.
“October’s
testing volume reflects our efforts to expand the commercial reach of CyPath Lung,” said Maria Zannes, President and Chief Executive
Officer of bioAffinity Technologies. “In addition to expanding physician adoption and strengthening relationships with existing
customers, we are taking additional steps to expand the reach of CyPath Lung and set the stage for long-term growth. We have expanded
our sales team. We are working with patient advocacy organizations to strengthen our connections within the lung cancer community, and
we are seeing significant advances in our R&D to apply our proprietary technology platform to asthma and COPD.”
CyPath
Lung is a noninvasive test that analyzes cell populations in sputum using flow cytometry and proprietary AI to help physicians assess
the likelihood of lung cancer by analyzing the lung microenvironment. The test is designed to complement existing imaging and clinical
assessment and provide physicians with additional information when determining appropriate next steps for patients.
bioAffinity
continues to advance its commercial strategy through direct physician engagement, distribution relationships and opportunities within
government healthcare systems. The Company is focused on increasing awareness and utilization of CyPath Lung among pulmonologists and
other healthcare providers while building on its growing base of ordering physicians and repeat testing activity.
About
CyPath Lung
CyPath
Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk
for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in
patient sputum that indicate malignancy. CyPath Lung incorporates proprietary antibodies and a novel fluorescent porphyrin that is preferentially
taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung demonstrated
92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk
for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV may help inform physician decision-making
when evaluating whether further invasive procedures are warranted. CyPath Lung is marketed as a Laboratory Developed Test (LDT), is not
intended for use as a sole diagnostic tool and should be considered alongside other clinical findings. For more information, visit www.cypathlung.com.
About
bioAffinity Technologies, Inc.
bioAffinity
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum
cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity
and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision
Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement
Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.
Forward-Looking
Statements
Certain
statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.
Words such as “may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”
“plan,” “intend” or similar expressions, or statements regarding intent may identify forward-looking statements,
although not all forward-looking statements contain these words. These forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties that could cause actual results to differ materially, including the Company’s
ability to sustain physician demand and convert commercial efforts into reimbursable testing and revenue; variability in monthly testing
volume; reimbursement coverage, payment rates, denials and collection delays; the ability to establish and maintain distribution relationships
and obtain government healthcare business; and the possibility that research will not establish the clinical performance or utility needed
for new applications or lead to commercially viable products. Historical testing volume does not establish future growth, revenue or
profitability. Additional risks and uncertainties are described in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2025 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Readers are cautioned
not to place undue reliance on forward-looking statements. These statements speak only as of the date of this release, and the Company
undertakes no obligation to update them, except as required by applicable law.
Contact
bioAffinity
Technologies
Julie
Anne Overton
Director
of Communications
investors@bioaffinitytech.com